The CCR5 Delta32, CCR2 64I, SDF1 3'A, and CCR5 promoter 59029 polymorphisms have been suggested to influence HIV-1 disease progression. Furthermore, the CCR5 Delta32 and the CCR2 64I polymorphisms have been associated with various other diseases. The purpose of the present study was to develop a multiplex assay for the simultaneous determination of these four polymorphisms. Results obtained with the multiplex assay were compared to results obtained by conventional RFLP-PCR and no differences were observed. The multiplex assay offers a quick tool for the determination of the CCR5 Delta32, CCR2 64I, SDF1 3'A, and CCR5 promoter 59029 A/G polymorphisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-1759(01)00349-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting CCR5: A central approach to HIV treatment and cure strategies.
Virology
December 2024
Section of Infectious Diseases, Department of Internal Medicine, Yale University, New Haven, CT, United States. Electronic address:
CCR5, a co-receptor critical for R5-tropic HIV entry into host cells, remains a key target for therapeutic interventions. HIV utilizes CCR5, expressed on T cells and macrophages, to facilitate viral entry. Genetic variants, such as the CCR5Δ32 homozygous mutation that confers protection to HIV infection, have made CCR5 a main target for gene-editing technologies, small-molecule inhibitors, and monoclonal antibody-based therapies.
View Article and Find Full Text PDF30 years of HIV therapy: Current and future antiviral drug targets.
Virology
December 2024
Section of Infectious Diseases, Department of Internal Medicine, Yale University, New Haven, CT, 06510, USA. Electronic address:
Significant advances in treatment have turned HIV-1 into a manageable chronic condition. This has been achieved due to highly active antiretroviral therapy (HAART), involving a combination regimen of medications, including drugs that target Reverse Transcriptase, Protease, Integrase, and viral entry, explored in this review. This paper also highlights novel therapies, such as Lenacapavir, and avenues toward functional cure targeting the CCR5 co-receptor, including the Δ32 mutation.
View Article and Find Full Text PDFDysregulated Vitamin D, , , and Δ32 Gene Variations are Associated with Coronary Artery Disease.
Discov Med
November 2024
Department of Medical Lab Technology, Prince Fahad Bin Sultan Chair for Biomedical Research, Faculty of Applied Medical Sciences, University of Tabuk, 71491 Tabuk, Saudi Arabia.
Article Synopsis
- - Insufficient vitamin D levels are linked to chronic conditions like cancers, diabetes, and cardiovascular diseases, particularly coronary artery disease (CAD), with enzymes involved in vitamin D metabolism potentially affecting these levels.
- - The study analyzed genetic mutations (rs1562902 C > T, rs12255372 G > T, and Δ32 bp deletion) for their relationships with reduced vitamin D and CAD risk, using specific PCR techniques for genotyping.
- - Results showed significant associations between certain genetic variants and higher CAD risk, particularly the rs1562902 C > T genotype and Δ32 deletion, suggesting these mutations may be genetic indicators for CAD susceptibility.
Impact of CCR5Δ32 on the risk of infection, Staphylococcus aureus carriage, and plasma concentrations of chemokines in Danish blood donors.
EBioMedicine
November 2024
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Article Synopsis
- The CCR5 receptor is linked to susceptibility to Staphylococcus aureus leukotoxin ED, and researchers investigated the effects of the CCR5Δ32 deletion on S. aureus infection and nasal carriage in a large Danish blood donor study.
- Analysis involved over 95,000 participants, examining various health outcomes and inflammatory markers through sophisticated statistical methods.
- Findings indicated that CCR5Δ32 does not significantly affect the risk of S. aureus-related infections or nasal carriage, although it was associated with higher levels of certain chemokines in individuals with the deletion.
Investigating the Potential Impact of CCR5-Δ32 Variant on COVID-19 Outcome: A Case-Control Study in Iranian Population.
Iran J Public Health
August 2024
Department of Genetics, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Background: The impact of CCR5-Δ32 on COVID-19 outcomes has been the focus of much research. This genetic variant may protect against SARS-CoV-2 infection, while others have produced conflicting results. Given the controversial results of previous research on different populations, we aimed to investigate the possible association between the CCR5-Δ32 variant and COVID-19 severity in an Iranian population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!